Floatz Rating
C34/100
Confidence
Indicative
Sponsor
Merck Sharp & Dohme LLC
Modality
Small molecule
Development Phase
Phase 1
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
19High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02698176CT.gov A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Advanced Solid Tumors (MK-8628-006) | — | Terminated | — | — | — |
NCT02259114CT.gov A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003) | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Indicative
Detailed axis rationale is planned and will be published soon.
Same indication · Nut Midline Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Birabresib (this asset) | Merck Sharp & Dohme LLC | P1 | C · 34 |
| Cudc-907 | Curis, Inc. | P1 | CC |
| Molibresib | GlaxoSmithKline | P1 | CC |
| Abemaciclib | National Cancer Institute (NCI) | P1 | CC |
| Bet Bromodomain Inhibitor Zen-3694 | National Cancer Institute (NCI) | P1 | CC |
| ep31670 | Epigenetix, Inc. | P1 | CC |
| mt-4561 | Tanabe Pharma America, Inc. | P1/2 | NR |
Other indications for Birabresib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Glioblastoma | — | P2 | C · 38 |
| Acute Myeloid Leukemia | — | P1/2 | C · 35 |
| Castration-Resistant Prostate Carcinoma | — | P1 | C · 34 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Birabresib in Nut Midline Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/birabresib-nut-midline-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →